Press Releases

 Filter by Provider

Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communities most affected by infectious diseases.

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows:

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P).

Hartgraves & the Adventure in Time!

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025.RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

Interviews with fifty failed startup managers reveal that most collapses stemmed from weak leadership, not poor ideas. The findings highlight seven recurring management mistakes and emphasize that effective leadership is a learned skill, essential for building clarity, trust, and lasting team success.

Dubai, UAE, October 19, 2025 -- ChillPlay Games today announced a significant milestone for its mobile title Over Hit: Hero Fight, which has surpassed 50,000 downloads on Google Play. Coinciding with this momentum, the studio released a major technical update that rebuilds the game from the ground up on a modular engine architecture based on Unity 6 and debuts AI Node, a new in-house module currently in beta. AI Node is powered by Claude AI by Anthropic and leverages the Model Context Protocol (MCP) during the game assembly process to deliver smarter enemies and more coherent level design.

Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here.

São Paulo / New York, 2025 — As a global asset management firm committed to bridging traditional finance and the digital future, Chainvest Gestora de Recursos Ltda. is driving the compliant development and inclusive adoption of blockchain finance and digital asset management across Latin America. At the heart of this mission stand two key leaders — João Pedro and Mariana Silva — whose extensive international investment banking and digital asset management experience form the strategic core of Chainvest’s global growth.

New York — 2025. The global landscape of blockchain finance and digital asset management welcomes a new force. Headquartered in New York, Chainvest Gestora de Recursos Ltda. officially announces its entry into the Brazilian market, marking the beginning of its strategic expansion across Latin America. This move represents a new chapter in the integration of digital finance with the global economy and underscores the company’s commitment to compliance and democratizing blockchain-based investment opportunities in the region.

Faeth Therapeutics today announced results from the international DICE trial, a randomized phase 2 study of sapanisertib (TAK228) plus weekly paclitaxel versus paclitaxel alone in women with platinum-resistant or recurrent epithelial ovarian or fallopian tube cancer. The trial was selected for a Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and met its pre-ordained statistical design and there is sufficient evidence of a positive signal to justify a larger phase 3 design.

Have you ever considered how you would appear if you were to wear someone else’s face? Or, would you rather effortlessly create some realistic, fun, and entertaining face swaps? Or Face swap Video is exactly what you need. You can swap faces in photos, memes, avatars, and even famous works of art with just a […]

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and safety data from partner GenFleet Therapeutics’ Phase 1/2 monotherapy study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor (VS-7375 outside of China) for patients with KRAS G12D mutant advanced pancreatic ductal adenocarcinoma (PDAC). Among 59 heavily pre-treated patients with advanced disease, who received two or more prior lines of therapy, an overall response rate (ORR) of 41% was achieved at the monotherapy recommended Phase 2 dose (RP2D) of 600 mg daily (QD). The updated data were featured in a late-breaking abstract for oral presentation by GenFleet Therapeutics at the European Society for Medical Oncology (ESMO) Congress 2025 on October 19, 2025, in Berlin, Germany.

Tubulis today announced positive early clinical data from its NAPISTAR1-01 Phase I/IIa study (NCT06303505) in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Principal Investigator, Dr. Antonio González-Martín, Director Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra, presented the results of Tubulis’ lead antibody-drug conjugate (ADC), TUB-040, in platinum-resistant high-grade serous ovarian cancer (PROC-HGSOC), with a focus on dose levels 1.67 – 3.3 mg/kg. This is the first clinical data to validate Tubulis’ proprietary Tubutecan technology, establishing clear proof of concept for the company’s most advanced ADC targeting NaPi2b.

Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis. For the key secondary endpoint of OS, XTANDI plus leuprolide reduced the risk of death by 40.3% compared to leuprolide alone (Hazard Ratio [HR]: 0.597; 95% Confidence Interval [CI], 0.444-0.804; p=0.0006), making this the first and only androgen receptor inhibitor-based regimen to demonstrate an OS benefit in nmHSPC with high-risk BCR.1 The 8-year overall survival was 78.9% (95% CI, 73.9% to 83.1%) among patients receiving XTANDI plus leuprolide and 69.5% (95% CI, 64.0% to 74.3%) among patients taking leuprolide alone.1 A numerical improvement in OS with XTANDI as monotherapy compared to leuprolide alone (HR: 0.83 [95% CI, 0.63-1.095; p=0.1867) did not reach statistical significance.1 These data are being presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany and have been simultaneously published in The New England Journal of Medicine.

October 19, 2025 -- The Crisis of the Sister City Mission: Transparency, Accountability, and the Public Trust

October 19, 2025 -- Amid the swirl of new titles and industry deals at the 2025 Frankfurt Book Fair, one event stood apart for its soul-searching depth: the inaugural Xuemo World Literature Forum, themed "Eternal Love: Creating Meaning in the Void."

Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option. These late-breaking results will be presented today during a proffered paper session (LBA21) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.

Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated patients, the median OS was 22.7 months (95% CI, 14.1, 32.6), after a median follow-up of 48.2 months. The four-year OS rates were 49% (95% CI, 35, 62) and 31% (95% CI, 16, 47) for treatment-naïve and previously treated patients, respectively. These data, from pre-specified secondary trial endpoints, will be presented today in an oral presentation (1849MO) at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, and have been simultaneously published in the Journal of Clinical Oncology.

Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. These findings will be presented today during a late-breaking oral session at the 2025 European Society for Medical Oncology (ESMO) Congress (Abstract #LBA20) and simultaneously published in The New England Journal of Medicine.

SAN FRANCISCO, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Arbrest, a rising DTC home furnishing brand, today announced the launch of its independent website (www.arbrest.com). Guided by its “Gentle Design” philosophy, Arbrest blends natural materials with modern aesthetics to create furniture that gives homes room to breathe, shift, and settle. The brand’s vision, “Where Nature Rests, Life Finds Its Rhythm,” is to help every household find its own rhythm of living.

Based Eggman | $GGs Crypto Presale | Gaming & Social - Fi on Base Layer-2.

Alpha Wealth Group introduces enhanced wealth structuring solutions aimed at securing multi-generational prosperity for high-net-worth clients in a rapidly evolving financial world.

The founder of Le Muse Magazine consolidates her global presence and redefines the creative power of the region at major international fashion weeks.

Divy Fashion Mart pioneers a groundbreaking "investment shopping" model, allowing consumers to earn equity with every purchase, revolutionizing retail.

DMA Yachting reports that after evaluating over 200 crewed yachts across Greek and Mediterranean yacht shows in 2025, the firm sees a significant value opportunity driven by a booming fleet, fierce competition, and savvy buyers.

Metamorphosis Collective, co-founded by Jeremiah Dupin and Jakob Gricar, introduces a transformative 12-week program designed for high-achieving women to restore balance and reclaim their power.

The Underfront Co., Wilmington's unique underground cocktail bar, offers craft cocktails, local brews, and live music in a cozy, intimate setting.

AdSolve Media, led by founder Amelia Sigamony, has been recognized as the Best Digital Marketing Agency in Edmonton, offering small and medium-sized businesses access to world-class strategies at an affordable price.

BEIJING, CHINA - Media OutReach Newswire - 19 October 2025 - A thousand years ago, delivering fresh lychees from southern China to the capital, Chang'an,...

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) --

Over 40 Vibes releases new article: 22 key life lessons from the author's first 40 years, on self-improvement, mindset shifts, resilience, relationships, and fulfillment—targeted at adults over 40.

Beijing, China () October 18, 2025 -- Xi Jinping Thought on Culture was put forward in 2023 at a two-day national meeting on the work of public communication and culture.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) --

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance.

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Center’s Department of Medical Oncology at the 2025 European Society of Medical Oncology (ESMO) Annual Congress.

Local electrical contractor Triad Electric Solutions has implemented state-of-the-art thermal imaging technology across its operations, significantly improving diagnostic capabilities and reducing service call duration. The Greensboro-based company, led by owner David Angel, reports that the new technology has cut electrical repair diagnostic time in half while improving accuracy in identifying potential electrical hazards.

CODE 4 PRIVATE SECURITY - SAN JOSE has been honored with the prestigious Industry Excellence Award for Client Retention Standards, recognizing the company's exceptional performance in maintaining long-term partnerships across California and Nevada markets. The award acknowledges organizations that demonstrate superior client satisfaction rates and service consistency in the competitive security sector.

LONDON, GB / ACCESS Newswire / October 18, 2025 / Research Vision Limited, a London-headquartered wealth management firm overseeing more than £1.4 billion in client assets, today announced its intention to float on the London Stock Exchange (LSE), one of the world's most respected and internationally connected financial markets.

Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase 1/2 CLARA trial, which evaluated the safety, efficacy and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor) in patients with corneal edema secondary to corneal endothelial dysfunction. The findings were presented at Cornea Day during the American Academy of Ophthalmology (AAO) meeting in Orlando, FL.

NEW YORK CITY, NY / ACCESS Newswire / October 18, 2025 / Following its successful debut, the TOZO HT3 Over-Ear Headphones are continuing to capture attention across the audio world - and for good reason. With its immersive spatial audio, premium Hi-Res sound quality, and AI-enhanced smart features, the HT3 transforms every listening moment into an experience that surrounds you.

Charleston native Brian McCrudden, known professionally as WILLSTFU, has made local history by becoming the first Charleston-based country artist to surpass 10,000 streams at just 18 years old. The young country artist’s milestone marks a major step forward in the region’s growing pop-country scene.

Zia Sabir’s Commitment to Responsible Growth, Strategic Alliances, and Industry Excellence Earns ADISA’s 2025 Distinguished Service Award

NEW YORK CITY, NY / ACCESS Newswire / October 18, 2025 / New to The Street, one of the nation's longest-running business television brands airing as sponsored programming on Bloomberg Television (6:30 PM EST) and Fox Business, announces the broadcast of its 694th episode tonight.

Get Me to Costa Rica! by author Layne Balke inspires transformation and stress relief through Costa Rica’s tranquil lifestyle and self-help philosophy.

Advanced Bio Solutions Group, founded by Dr. Beran Parry, is reshaping the future of functional health, natural medicine and health education with cutting-edge protocols, highly effective health transformation programs and natural medicines, and innovative training programs.